Refining Treatment Approaches for Chronic Lymphocytic Leukemia - Episode 16
PI3K inhibitors for R/R CLL
William Wierda, MD, PhD, University of Texas MD Anderson Cancer Center, John Allan, MD, Weill Cornell Medicine, Ehab Atallah, MD, Medical College of Wisconsin, Steven Coutre, MD, Stanford University Medical Center, Nicole Lamanna, MD, Herbert Irving Comprehensive Cancer Center, Jennifer Woyach, MD, Ohio State University
An overview of data for PI3K inhibitors for in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
Video Player is loading.
Related Content:
